2020
Characteristics of Serotype 3 Invasive Pneumococcal Disease before and after Universal Childhood Immunization with PCV13 in Massachusetts
Lapidot R, Shea KM, Yildirim I, Cabral HJ, Pelton SI, Health T. Characteristics of Serotype 3 Invasive Pneumococcal Disease before and after Universal Childhood Immunization with PCV13 in Massachusetts. Pathogens 2020, 9: 396. PMID: 32455770, PMCID: PMC7281000, DOI: 10.3390/pathogens9050396.Peer-Reviewed Original ResearchPneumococcal conjugate vaccineIPD casesIncidence rate ratiosIPD incidencePCV-13Disease characteristicsSerotype 3 invasive pneumococcal diseaseInvasive pneumococcal disease incidenceImpact of PCV13Presence of comorbiditiesInvasive pneumococcal diseasePneumococcal disease incidenceUniversal childhood immunizationWaning of immunityPassive surveillance systemPCV13 dosePCV13 introductionVaccine effectivenessConjugate vaccineMassachusetts childrenPneumococcal diseaseClinical syndromeChildhood immunizationIncidence ratePCV13
2018
The relative invasive disease potential of Streptococcus pneumoniae among children after PCV introduction: A systematic review and meta-analysis
Balsells E, Dagan R, Yildirim I, Gounder PP, Steens A, Muñoz-Almagro C, Mameli C, Kandasamy R, Lavi N, Daprai L, van der Ende A, Trzciński K, Nzenze SA, Meiring S, Foster D, Bulkow LR, Rudolph K, Valero-Rello A, Ducker S, Vestrheim DF, von Gottberg A, Pelton SI, Zuccotti G, Pollard AJ, Sanders EAM, Campbell H, Madhi SA, Nair H, Kyaw MH. The relative invasive disease potential of Streptococcus pneumoniae among children after PCV introduction: A systematic review and meta-analysis. Journal Of Infection 2018, 77: 368-378. PMID: 29964140, DOI: 10.1016/j.jinf.2018.06.004.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseInvasive disease potentialPneumococcal conjugate vaccineNon-vaccine typesPCV introductionPneumococcal diseaseClinical syndromePneumococcal serotypesSurveillance of IPDDisease potentialSystematic reviewCurrent pneumococcal conjugate vaccinesYears of ageRandom-effects modelConjugate vaccineRoutine immunisationDisease presentationFuture vaccinesStreptococcus pneumoniaeSerotype 1SerotypesSyndromeCarriageChildrenVaccine
2017
Impact of PCV13 on Serotype 3 Invasive Pneumococcal Disease and Nasopharyngeal Carriage in Massachusetts’ Children
Lapidot R, Shea K, Little B, Yildirim I, Pelton S. Impact of PCV13 on Serotype 3 Invasive Pneumococcal Disease and Nasopharyngeal Carriage in Massachusetts’ Children. Open Forum Infectious Diseases 2017, 4: s467-s467. PMCID: PMC5631065, DOI: 10.1093/ofid/ofx163.1194.Peer-Reviewed Original ResearchPresence of comorbiditiesIPD casesPCV13 implementationYears of ageClinical syndromeSpeaker honorariaNP carriageNasopharyngeal carriageSerotype 3 invasive pneumococcal diseaseInvasive pneumococcal disease incidenceAge distributionEffectiveness of PCV13Impact of PCV13US census estimatesInvasive pneumococcal diseasePneumococcal disease incidenceAnnual incidence rateActive Surveillance NetworkAnnual prevalence rateIPD incidenceMerck vaccinePCV13 dosePneumococcal diseaseVaccination statusVaccine serotypes